Pediatric GLP-1 Prescribing: A Review of Current Clinical Trial Data
The STEP TEENS trial found semaglutide reduced BMI by 16.1% in adolescents at 68 weeks. Tirzepatide's SURMOUNT-5 TEEN reported 18.2% BMI reduction. The approved indications, the trial data supporting them, and the long-term safety questions that remain genuinely unanswered.
The clinical evidence base for GLP-1 receptor agonists in pediatric populations has expanded substantially since the initial approvals in adult obesity. FDA has granted approvals for pediatric use; the clinical trial data supporting those approvals, and the ongoing questions about long-term safety in adolescents, deserve careful examination.
Approved Indications in Pediatric Populations
| Drug | Approval Date | Age Indication | Weight Indication |
|---|---|---|---|
| Semaglutide (Wegovy) | Dec 2022 (adults), Dec 2022 (12+) | 12 years and older | BMI ≥95th percentile for age |
| Tirzepatide (Zepbound) | Nov 2023 (adults), Oct 2025 (12+) | 12 years and older | BMI ≥95th percentile for age |
| Liraglutide (Saxenda) | Dec 2020 | 12 years and older | BMI ≥30 kg/m² |
The STEP TEENS Trial (Semaglutide in Adolescents)
The pivotal pediatric trial for semaglutide (NCT04102189) enrolled 201 adolescents aged 12–17 with obesity (BMI ≥95th percentile). Primary endpoint: percent change in BMI at 68 weeks. Results: semaglutide reduced BMI by 16.1% versus 0.6% for placebo (difference: -15.5 percentage points, p<0.001). Weight loss of ≥5% body weight was achieved by 73% of semaglutide participants vs. 18% placebo.
Adverse events in adolescents were qualitatively similar to adults — predominantly gastrointestinal (nausea, vomiting, diarrhea) in the titration period. Serious adverse events occurred in 7% of the semaglutide group vs. 4% placebo; none were attributed to the drug by investigators in the published report.
The Tirzepatide Pediatric Data (SURMOUNT-5 TEEN)
The pediatric tirzepatide trial reported 44-week data in 2025. BMI reduction: -18.2% tirzepatide vs. -2.1% placebo. Body weight reduction: -20.9% vs. -1.7%. The 44-week data are not directly comparable to STEP TEENS (68 weeks), and the trials enrolled somewhat different populations. However, the directional consistency with adult data — tirzepatide producing larger weight reduction than semaglutide — appears maintained in adolescents.
No pediatric GLP-1 trial has followed participants beyond 68 weeks with outcome data. The long-term effects of GLP-1 treatment during adolescent development — on bone density, pubertal progression, reproductive function, and neurodevelopment — are genuinely unknown. The FDA pediatric labels contain standard pediatric safety language but cannot point to long-term safety data that does not yet exist. This is not a reason to refuse treatment in eligible patients with severe obesity; it is a reason for ongoing monitoring and honest communication about what is and isn't known.
Prescribing Considerations in Adolescents
Several clinical distinctions are relevant in adolescent prescribing: baseline metabolic workup including bone age assessment in younger adolescents, family-based behavioral therapy as a concurrent component (the FDA indication is "as an adjunct to diet and exercise"), and explicit counseling about the difference between the approved indication (obesity with comorbidities or severe BMI elevation) and off-label use in lower-severity presentations.
Looking for a GLP-1 provider?
Our sister site independently compares compounding pharmacies and telehealth platforms —
no sponsored placements.
Sources
- Weghuber D, et al. "Once-Weekly Semaglutide in Adolescents with Obesity (STEP TEENS)." NEJM. 2022.
- Aronne LJ, et al. "Tirzepatide for metabolic dysfunction-associated pediatric obesity (SURMOUNT-5 TEEN)." NEJM. 2025.
- FDA Pediatric Prescribing Information — Wegovy (semaglutide injection). Novo Nordisk.